Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Key Inclusion Criteria: * Previously treated individuals with inoperable metastatic colorectal cancer (mCRC) who are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or mismatch repair deficient (dMMR) and are excluded). * Histologically or cytologically confirmed adenocarcinoma originating in the colon or rectum (excluding appendiceal and anal canal cancers) who have progressed on or after 1 prior systemic therapy in the setting where curative resection is not indicated. This therapy must have included chemotherapy based on 5-fluorouracil (5-FU) or capecitabine with oxaliplatin and either bevacizumab, or for individuals with rat sarcoma (RAS) wild-type and left-sided tumors, bevacizumab, cetuximab, or panitumumab. * Measurable disease (Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria). * Individuals must have an eastern cooperative oncology group (ECOG) performance status of 0 or 1. * Life expectancy of at least 12 weeks. * Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and platelet counts * Adequate liver function. * Adequate renal function. Key Exclusion Criteria: * Prior anticancer therapy including chemotherapy, hormonal therapy, or investigational agents within 3 weeks or within at least 4 half-lives prior to magrolimab dosing (up to a maximum of 4 weeks), whichever is shorter. * Known v-raf murine sarcoma viral oncogene homolog B1 gene mutation (BRAF V600E) or MSI-H mutations or dMMR. * Persistent Grade 2 or more gastrointestinal bleeding. * Individuals with prior irinotecan therapy. * Clinically significant coronary artery disease or myocardial infarction within 6 months prior to inclusion. * Peripheral neuropathy of more than Grade 2 (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0). * Known dihydropyrimidine dehydrogenase deficiency. * Acute intestinal obstruction or sub-obstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colonic prosthesis. * Unhealed wound, active gastric or duodenal ulcer, or bone fracture. * History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4 gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominal abscesses 6 months prior to screening. * Uncontrolled arterial hypertension. * Thromboembolic event in the 6 months before inclusion (eg, transitory ischemic stroke, stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosis treated with anticoagulants. * Active central nervous system (CNS) disease. Individuals with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed. * Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening. * History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months. * Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient. * Known inherited or acquired bleeding disorders. * Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. * Second malignancy, except treated basal cell or localized squamous skin carcinomas, or localized prostate cancer. * Uncontrolled pleural effusion. Note: Other protocol defined Inclusion/Exclusion criteria may apply.